Lilly's Mirikizumab Superior to Cosentyx® (secukinumab) in a Phase 3 Study for Patients with Moderate to Severe Plaque Psoriasis

- Mirikizumab met the primary and all key secondary endpoints versus placebo at Week 16 and all key secondary endpoints versus Cosentyx® (secukinumab) at Week 16 and Week 52, including superiority in skin clearance at Week 52   - Lilly will submit data from OASIS-1 and 2 to regulatory authorities